Author: Liu, Zhao; Wei, Fei; Chen, Liang-Jun; Xiong, Hai-Rong; Liu, Yuan-Yuan; Luo, Fan; Hou, Wei; Xiao, Hong; Yang, Zhan-Qiu
Title: In Vitro and in Vivo Studies of the Inhibitory Effects of Emodin Isolated from Polygonum cuspidatum on Coxsakievirus B(4) Cord-id: jfihkob6 Document date: 2013_9_25
ID: jfihkob6
Snippet: The lack of effective therapeutics for Coxsackievirus B(4) (CVB(4)) infection underscores the importance of finding novel antiviral compounds. Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is one of the natural anthraquinone derivatives obtained from the root and rhizome of Polygonum cuspidatum. In the present study, the possibility of using emodin as a potential antiviral to treat CVB(4) infection was explored in vitro and in mice. Emodin reduced CVB(4) entry and replication on Hep-2 cells in
Document: The lack of effective therapeutics for Coxsackievirus B(4) (CVB(4)) infection underscores the importance of finding novel antiviral compounds. Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is one of the natural anthraquinone derivatives obtained from the root and rhizome of Polygonum cuspidatum. In the present study, the possibility of using emodin as a potential antiviral to treat CVB(4) infection was explored in vitro and in mice. Emodin reduced CVB(4) entry and replication on Hep-2 cells in a concentration- and time-dependent manner, with a 50% effective concentration (EC(50)) of 12.06 μM and selectivity index (SI) of 5.08, respectively. The inhibitory effect of emodin for CVB(4) entry and replication was further confirmed by a quantitative real time PCR (qPCR) assay. The results further showed that the mice orally treated with different dosages of emodin displayed a dose dependent increase of survival rate, body weight and prolonged mean time of death (MTD), accompanied by significantly decreased myocardial virus titers and pathologic scores/lesions. Moreover, emodin could inhibit CVB(4)-induced apoptosis in vitro and in vivo. Our results indicated that emodin could be used as potential antiviral in the post-exposure prophylaxis for CVB(4) infection.
Search related documents:
Co phrase search for related documents- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and addition assay: 1
- absence presence and liver cirrhosis: 1, 2, 3, 4, 5
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- active component and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- active component and addition assay: 1
- active component and addition assay time: 1
- active component and liver cirrhosis: 1
- acute respiratory syndrome and addition assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- acute respiratory syndrome and addition assay time: 1, 2, 3, 4
- acute respiratory syndrome and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- acute respiratory syndrome and lysis buffer: 1, 2, 3
- loading buffer and lysis buffer: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date